115
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Pan-Cancer Analysis of the N6-Methyladenosine Eraser FTO as a Potential Prognostic and Immunological Biomarker

, , &
Pages 7411-7422 | Published online: 29 Oct 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Yue Li, Dalei Zhou, Qing Liu, Weijie Zhu, Zulu Ye & Caiyun He. (2022) Gene Polymorphisms of m6A Erasers FTO and ALKBH1 Associated with Susceptibility to Gastric Cancer. Pharmacogenomics and Personalized Medicine 15, pages 547-559.
Read now

Articles from other publishers (4)

Xiangqing Ren, Xiaolong Tang, Tian Huang, Zenan Hu, Yuping Wang & Yongning Zhou. (2023) FTO plays a crucial role in gastrointestinal cancer and may be a target for immunotherapy: an updated review. Frontiers in Oncology 13.
Crossref
Su-Zhe Zhou, Ying-Lian Pan, Qing-Chun Deng, Chang-Jun Yin, De-Jiang Zhou, Ming-Liang Liu, Jun Zhou & Xiao-Jing Wu. (2023) A Prognostic Signature for Colon Adenocarcinoma Patients Based on m6A-Related lncRNAs. Journal of Oncology 2023, pages 1-13.
Crossref
Zhaotong Wang, Jiawang Zhou, Haisheng Zhang, Lichen Ge, Jiexin Li & Hongsheng Wang. (2022) RNA m 6 A methylation in cancer . Molecular Oncology 17:2, pages 195-229.
Crossref
Yifu Liu, Shengqiang Fu, Zhicheng Zhang, Siyuan Wang, Xiaofeng Cheng, Zhilong Li, Yi Ding, Ting Sun & Ming Ma. (2022) GRAMD1A Is a Biomarker of Kidney Renal Clear Cell Carcinoma and Is Associated with Immune Infiltration in the Tumour Microenvironment. Disease Markers 2022, pages 1-25.
Crossref